Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Survival of HIV-infected patients with compensated liver cirrhosis.

Tuma P, Jarrin I, Del Amo J, Vispo E, Medrano J, Martin-Carbonero L, Labarga P, Barreiro P, Soriano V.

AIDS. 2010 Mar 13;24(5):745-53. doi: 10.1097/QAD.0b013e3283366602.

PMID:
20154579
2.

Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease.

Merchante N, Girón-González JA, González-Serrano M, Torre-Cisneros J, García-García JA, Arizcorreta A, Ruiz-Morales J, Cano-Lliteras P, Lozano F, Martínez-Sierra C, Macías J, Pineda JA; Grupo Andaluz para el Estudio de las Enfermedades Infecciosas..

AIDS. 2006 Jan 2;20(1):49-57.

PMID:
16327319
3.

Incidence of liver cirrhosis in HIV-infected patients with chronic hepatitis B or C in the era of highly active antiretroviral therapy.

Tuma P, Medrano J, Resino S, Vispo E, Madejón A, Sánchez-Piedra C, Rivas P, Labarga P, Martín-Carbonero L, Barreiro P, Soriano V.

Antivir Ther. 2010;15(6):881-6. doi: 10.3851/IMP1630.

PMID:
20834100
4.

Impact of hepatitis B virus co-infection on response to highly active antiretroviral treatment and outcome in HIV-infected individuals: a nationwide cohort study.

Omland LH, Weis N, Skinhøj P, Laursen A, Christensen PB, Nielsen HI, Møller A, Engsig F, Sørensen HT, Obel N.

HIV Med. 2008 May;9(5):300-6. doi: 10.1111/j.1468-1293.2008.00564.x.

5.

Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 study in collaboration with the Mortalité 2005 survey, ANRS EN19).

Rosenthal E, Salmon-Céron D, Lewden C, Bouteloup V, Pialoux G, Bonnet F, Karmochkine M, May T, François M, Burty C, Jougla E, Costagliola D, Morlat P, Chêne G, Cacoub P; Mortavic/Mortalité 2005 Study Group..

HIV Med. 2009 May;10(5):282-9. doi: 10.1111/j.1468-1293.2008.00686.x.

6.

Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort.

Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katlama C, Zilmer K, Vella S, Kirk O, Lundgren JD; EuroSIDA Group..

AIDS. 2005 Mar 24;19(6):593-601.

PMID:
15802978
7.

Natural history of compensated viral cirrhosis in a cohort of patients with HIV infection.

Bruno R, Sacchi P, Puoti M, Maiocchi L, Patruno S, Carosi G, Filice G.

J Acquir Immune Defic Syndr. 2007 Nov 1;46(3):297-303.

PMID:
18172936
8.

Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus.

Martinez-Sierra C, Arizcorreta A, Díaz F, Roldán R, Martín-Herrera L, Pérez-Guzmán E, Girón-González JA.

Clin Infect Dis. 2003 Feb 15;36(4):491-8.

9.

The model for end-stage liver disease score is the best prognostic factor in human immunodeficiency virus 1-infected patients with end-stage liver disease: a prospective cohort study.

Murillas J, Rimola A, Laguno M, de Lazzari E, Rascón J, Agüero F, Blanco JL, Moitinho E, Moreno A, Miró JM; ESLD-HIV Working Group Investigators..

Liver Transpl. 2009 Sep;15(9):1133-41. doi: 10.1002/lt.21735.

10.

Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS.

Lewden C, Salmon D, Morlat P, Bévilacqua S, Jougla E, Bonnet F, Héripret L, Costagliola D, May T, Chêne G; Mortality 2000 study group..

Int J Epidemiol. 2005 Feb;34(1):121-30.

11.
12.

Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study).

Rosenthal E, Poirée M, Pradier C, Perronne C, Salmon-Ceron D, Geffray L, Myers RP, Morlat P, Pialoux G, Pol S, Cacoub P; GERMIVIC Joint Study Group..

AIDS. 2003 Aug 15;17(12):1803-9.

PMID:
12891066
13.

Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease.

Neff GW, Bonham A, Tzakis AG, Ragni M, Jayaweera D, Schiff ER, Shakil O, Fung JJ.

Liver Transpl. 2003 Mar;9(3):239-47.

14.

Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.

Jevtović DO, Salemović D, Ranin J, Pesić I, Zerjav S, Djurković-Djaković O.

HIV Med. 2007 Mar;8(2):75-9.

15.

Long-term follow-up of liver transplanted HIV/hepatitis B virus coinfected patients: perfect control of hepatitis B virus replication and absence of mitochondrial toxicity.

Tateo M, Roque-Afonso AM, Antonini TM, Medja F, Lombes A, Jardel C, Teicher E, Sebagh M, Roche B, Castaing D, Samuel D, Duclos-Vallee JC.

AIDS. 2009 Jun 1;23(9):1069-76. doi: 10.1097/QAD.0b013e32832c2a37.

PMID:
19417577
16.

Natural history of compensated and decompensated HCV-related cirrhosis in HIV-infected patients: a prospective multicentre study.

Girón-González JA, Brun F, Terrón A, Vergara A, Arizcorreta A.

Antivir Ther. 2007;12(6):899-907.

PMID:
17926644
17.

Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study.

Palella FJ Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, Holmberg SD; HIV Outpatient Study Investigators..

J Acquir Immune Defic Syndr. 2006 Sep;43(1):27-34.

PMID:
16878047
18.

Outcome and prognosis factors in HIV-infected hemodialysis patients.

Tourret J, Tostivint I, du Montcel ST, Bragg-Gresham J, Karie S, Vigneau C, Guiard-Schmid JB, Deray G, Bagnis CI.

Clin J Am Soc Nephrol. 2006 Nov;1(6):1241-7.

19.
20.

Is there evidence for an increase in the death rate from liver-related disease in patients with HIV?

Mocroft A, Soriano V, Rockstroh J, Reiss P, Kirk O, de Wit S, Gatell J, Clotet B, Phillips AN, Lundgren JD; EuroSIDA Study Group..

AIDS. 2005 Dec 2;19(18):2117-25.

PMID:
16284461
Items per page

Supplemental Content

Support Center